This activity is designed for clinical endocrinologists and other healthcare professionals involved in the treatment of patients with type 2 diabetes.

Diabetes is increasing in incidence, prevalence, and importance as a chronic disease throughout the world. The importance of protecting the body from hyperglycemia cannot be overstated, as the direct and indirect effects on the human vascular system are the major source of morbidity and mortality associated with diabetes. Therefore, in order to prevent the complications of type 2 diabetes, physicians need to know how, when, and in whom to initiate and intensify insulin therapy.

All educational activities are accessible via a PC (Windows 2000/XP/Vista/7) or Mac (Mac OS 10.x or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. Windows Media Player or compatible alternative, sound card, and speakers are required for streamed audio. The latest version of the Adobe Flash Player is suggested (please download here) for video programs. A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.

Declaration of Disclosure and Conflicts of Interest

It is the policy of AACE to ensure balance, independence, objectivity and scientific rigor in all of its CME activities. Presentation content may include discussion of an unlabeled or an investigational use of a product. AACE requires that participating faculty disclose to the audience any product(s) and its use(s) discussed in the educational activity that are unapproved/unlabeled for the use by the FDA or still considered investigational in nature.

Everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships. “Relevant financial relationships” are financial relationships in any amount occurring within the past 12 months that create a conflict of interest. AACE requires speakers, faculty, CME Committee and other individuals who are in a position to control the content of this educational activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly evaluated by AACE for fair balance, scientific objectivity of studies mentioned in the presentation and educational materials used as basis for content, and appropriateness of patient care recommendations.

The intent of this disclosure is not to prevent a speaker with commercial affiliations from presenting, but rather to provide learners with information from which they may make their own judgments. Informed learners are the final safeguards in assuring that a CME activity is independent from commercial influence.

CME Accreditation Committee Disclosures

Dr. David S.H. Bell reports that he has received speaker honoraria from Bristol-Myers Squibb/AstraZeneca, Boehringer-Ingelheim GmbH/Eli Lilly and Company, Santarus Inc., and Novo Nordisk A/S, and consulting fees from Bristol-Myers Squibb. Dr. Bell has no conflicts of interest.

Dr. Felice A. Caldarella reports that he has received speaker honoraria from Novo Nordisk A/S; and research grant support from Boehringer Ingelheim GmbH and Eli Lilly and Company. Dr. Caldarella has no identified conflicts of interest.

Dr. Marc J. Laufgraben reports that he does not have any relevant financial relationships with any commercial interests. Dr. Laufgraben has no identified conflicts of interest.

Dr. Joseph M. Tibaldi reports that he has received speaker honoraria from Daiichi Sankyo Company, Limited and Merck & Co., Inc.; and consultant and speaker honoraria from Novo Nordisk A/S. Dr. Tibaldi has no identified conflicts of interest.

Faculty Disclosures

Dr. Mary Korytkowski reports that she has received research support for her role as principal investigator from sanofi-aventis U.S. LLC. She also reports that her presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Korytkowski has an identified conflict of interest and it has been resolved accordingly. She has been advised by the AACE CME Accreditation Committee to base her presentation and recommendations on the best available, preferably published evidence/information.

Dr. Dace L. Trence reports that she has received research grant support from Eli Lilly and Company and Novo Nordisk A/S; is a stockholder of Medtronic, Inc.; and has received research grant support from and is a stockholder of sanofi-aventis U.S. LLC. She also reports that her presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Trence has an identified conflict of interest and it has been resolved accordingly. She has been advised by the AACE CME Accreditation Committee to base her presentation and recommendations on the best available, preferably published evidence/information.

Dr. Guillermo Umpierrez reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Umpierrez has no identified conflicts of interest.

Program management jointly provided by North American Center for Continuing Medical Education, LLC and Horizon CME